Navigation Links
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
Date:3/18/2013

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ --

Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor.

     (Logo: http://photos.prnewswire.com/prnh/20130221/595427)

The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of VBY-891 in healthy adults.

"The initiation of this Phase 1 trial represents a significant development objective for Virobay's collaboration with LEO Pharma," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay. "Virobay has plans to initiate clinical studies with additional cathepsin inhibitors during 2013 as we seek to develop new therapies for underserved diseases. Published prelinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with dermatological disorders such as psoriasis. In addition, our own preclinical data with selective cathepsin S inhibitors has demonstrated efficacy in models of both psoriasis and atopic dermatitis," stated Robert Booth . "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-891."

"Reaching this important milestone in our collaboration with Virobay brings us one step closer to provide an oral treatment for psoriasis patients. We believe that VBY-891 has the potential to provide an oral treatment that may alleviate symptoms of psoriasis. LEO Pharma strives to constantly expand and improve treatment options for patients and this is an important example of our commitment to meeting patient needs. To the best of our knowledge, the VBY-891 compound has the potential to be the first in class on the market," said Kim Kjøller, Senior Vice President, Global Development, LEO Pharma.

Background

About Cathepsin S and VBY-891

Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes the final proteolytic step in the processing of invariant chain in specific antigen presenting cells. This step is essential in the maturation and loading of MHC Class II with antigenic peptides and subsequent activation of CD4+ T cells. Continuous presentation of antigenic self-peptides is thought to be involved in the maintenance of chronic disease in autoimmune disorders, including psoriasis. Inhibition of cathepsin S is likely to result in a reduction in antigen presentation without an impact on innate immunity.

VBY-891 is a next generation cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of purified cathepsin S. It has picomolar inhibitory potency against the cathepsin S enzyme and nanomolar inhibitory potency in cellular assays. VBY-891 is also highly selective against human cathepsins L, B, F and K. Sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker. VBY-891 shows potent inhibitory activity in models of autoimmunity and neuropathic pain. Therefore, inhibition of cathepsin S may have therapeutic potential across a range of dermatological conditions.

About the collaboration

The multi-million dollar collaboration between Virobay Inc. and LEO Pharma A/S was entered in 2012 when LEO Pharma in-licensed the promising compound from Virobay. The collaboration agreement involves up-front payment to Virobay of USD 7m, followed by milestone payments totalling up to USD 300m and tiered to royalties. The compound has been tested in pre-clinical studies and the project is now entering the next phase - a phase 1 clinical trial in healthy human volunteers. After this trial has been completed, the plan is to do testing on psoriasis patients later this year. If the process proceeds as planned, the collaboration may result in an oral treatment for psoriasis in 6-7 years.

About Virobay, Inc.

Founded in 2006, Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a class of enzymes that are key mediators in a variety of diseases, including autoimmunity, neuropathic pain, liver disease, cancer and cardiovascular disorders. Virobay's clinical pipeline currently includes product candidates in autoimmune disease, neuropathic pain and liver fibrosis. For more information, please visit http://www.virobayinc.com

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs approximately 5,000 people worldwide.

For more information, visit http://www.leo-pharma.com.


'/>"/>
SOURCE Virobay, Inc. and LEO Pharma A/S
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Educating, Informing, and Successfully Preparing the Marketplace for New Bio-Pharma Products
2. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
3. Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at 2013 AAN Annual Meeting
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Sagent Pharmaceuticals Selects ProspectoRx and Clinical Pharmacology
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
7. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
8. Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation
9. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
10. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
11. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016   ... Douglas Hoey , RPh, MBA issued the following statement ... analysis released by the Centers for Medicare ... concerns raised by NCPA, beneficiary advocates and others: ... have raised. We are still reviewing the full CMS ...
(Date:2/12/2016)... 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in the ... Okaloosa County Emergency Medical Services (EMS) consisting of ... LT2 van. Quality Emergency Vehicles in Lecanto, FL ... sale.  This is the latest in Demers, ongoing expansion of ... at Demers. --> Benoit LaFortune , Executive Vice ...
(Date:2/12/2016)... Feb. 12, 2016  Memorial Hermann Health System has ... Howard to bring a one-of-a-kind experience to pediatric ... cutting-edge technologies such as 360-degree video and Google Cardboard, ... then literally – giving the patients and their families ... was all caught on video . ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 ... ... today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced ... will recruit top students from U.S. universities who will draw from Siemens’ ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center ... Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop event ... The workshops cover a broad range of topics, including coaching skills, the scientific ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned ... charity drive that will raise funds earmarked to purchase computers and software for Mrs. ... , “My school is in a low-income area and has more than 60 2nd ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset Protection, a full ... of the latest charity campaign in their community enrichment program. Art Expression utilizes ... worthy cause are currently being accepted at: http://artexpressioninc.org/ . , Art Expression ...
Breaking Medicine News(10 mins):